All manuscripts
Publications VST Cells G-Rex®10

Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay

Published Journal Cytotherapy

Share
12 pages Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay — Cytotherapy, 2021

Overview

The authors used a high-throughput assay to optimize cytokine conditions for VST expansion. Results showed IL-15/IL-6 was effective. These findings were validated by scaling up cultures in G-Rex® 10 devices, which produced functional T cells equivalent to standard protocols.

What this paper found

A 96-well, 13-color flow cytometry screen identified IL-15 plus IL-6 as a cytokine pair that expands cytomegalovirus-specific T cells as well as the standard IL-4 plus IL-7, while skewing products toward CD8+ cells. Using donor PBMCs pulsed with IE1 and pp65 peptide pools, one plate tested 40 cytokine combinations with only 1 × 10^7 cells. After 10 days, IL-15/IL-6 expanded CD3+ cells a median 17.1-fold over no-cytokine controls versus 13.8-fold for IL-4/IL-7; it yielded 2.8-fold more CD8+ cells, whereas IL-4/IL-7 yielded 2.1-fold more CD4+ cells. Median IFN-γ-producing CD3+ cells were 19.3% and 16.3%. In G-Rex® 10 vessels, IL-15/IL-6 cells gave 638 ± 297 IFN-γ ELISpot spots per 100,000 cells versus 555 ± 230 with IL-4/IL-7.

Note: In vitro study on donor cells; the authors observed that some donors expanded better in IL-4/IL-7 and others in IL-15/IL-6.

This demonstrates that cells grown in IL-15/IL-6 were functionally equivalent to cells grown in IL-4/IL-7 when cultured to clinical scale and that the high-throughput screening method can reliably optimize product development. — Christopher A. Lazarski, Anushree A. Datar, Emily K. Reynolds, Michael D. Keller, Catherine M. Bollard, Patrick J. Hanley, Cytotherapy

Study details

Authors
Christopher A. Lazarski, Anushree A. Datar, Emily K. Reynolds, Michael D. Keller, Catherine M. Bollard, Patrick J. Hanley
Institution
Center for Cancer and Immunology Research, Children’s National Hospital, Washington, DC, USA · Division of Allergy and Immunology, Children’s National Hospital, Washington, DC, USA · Division of Blood and Marrow Transplantation, Children’s National Hospital, Washington, DC, USA · The George Washington University Cancer Center, Washington, DC, USA
Journal
Cytotherapy
Year
2020
PMID / PMC
PMID: 32921560 · PMC
G-Rex® model(s)
G-Rex®10
Cell type(s)
VST Cells
Application area
Infectious disease
Study phase
Preclinical

How G-Rex® was used

To confirm the 96-well screening results at clinical scale, 1–1.5 × 10^7 PBMCs were pulsed with IE1 and pp65 peptide libraries and cultured in G-Rex® 10 gas permeable chambers, resuspended in 1 mL of complete medium and then topped up with 29 mL of medium containing either IL-4/IL-7 or IL-15/IL-6. On day 7, 15 mL of medium was replaced with fresh medium and cytokines, and cells were cultured for 3 more days. Cells from the G-Rex® 10 vessels were then tested in IFN-γ ELISpot assays, where IL-15/IL-6 and IL-4/IL-7 products gave equivalent CMV-specific responses.

Explore related

Full citation

Lazarski CA, Datar AA, Reynolds EK, Keller MD, Bollard CM, Hanley PJ. Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay. Cytotherapy. 2021;23(1):65-76.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →